Latest Tanabe Pharma News & Updates

See the latest news and media coverage for Tanabe Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tanabe Pharma

Pharmaceutical company specializing in prescription medicines

tanabe-pharma.com

Headquarters: Osaka, Japan
Founded year: 1678
Company type: Public company
Number of employees: 5,000–10,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Tanabe Pharma

In short: Tanabe Pharma rebranded following its acquisition by Bain Capital and sold its global ALS drug business to Shionogi for $2.5 billion.

Company announcements

Today Tanabe Pharma

Tanabe Pharma receives approval in Japan for additional indication of generalized Myasthenia Gravis

The company obtained regulatory approval on September 16, 2026, for UPLIZNA® to treat this condition.

August 18 Tanabe Pharma

Tanabe Pharma licenses MT-7117 rights to LEO Pharma

The deal secures up to $435 million in upfront and milestone payments, funding reinvestment into its Japanese research pipeline.

July 3 Tanabe Pharma

Tanabe Pharma agrees to transfer subsidiary and product approvals

The subsidiary Tanabe Pharma Factory and marketing approvals for 17 products will be transferred to Towa Pharmaceutical, completing in stages from late 2026.

June 26 Tanabe Pharma

Tanabe Pharma announces regulatory approval of CANALIA Tablets in Thailand

The drug combines a DPP-4 inhibitor and SGLT2 inhibitor, targeting the estimated 6.4 million diabetes patients in Thailand.

Media coverage

Today BioPharm International

Japan Approves Tanabe Pharma's Inebilizumab for Myasthenia Gravis | BioPharm International

Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.

August 18 Fierce Biotech

Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod

Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from...

August 6 Yahoo Finance

Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs

ENERGI-F703DFU is a topical small-molecule gel that is intended to promote healing of DFUs by modulating cellular energy pathways. "Energenesis and Taiwan Tanabe to develop...

July 7 MarketWatch

Yomiuri: Towa Pharmaceutical Aims to Boost Production Capacity with Planned Acquisition of Tanabe Pharma Subsidiary

Towa Pharmaceutical Co., a major Japanese generic drugmaker, aims to "establish a system to increase production as soon as possible" amid concerns over a supply...

Never miss news about Tanabe Pharma

Track Tanabe Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tanabe Pharma competitors & trending companies

Browse news for competitors to Tanabe Pharma and other trending companies.